The fragment-based drug discovery market is projected to grow at an annualized rate of ~10%, {till 2030}
Roots Analysis has done a detailed study on Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030., covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 170+ page report, which features 55+
figures and 80+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html
Key
Market Insights
§
Over 85 firms are involved in providing fragment-based drug
discovery-related services; of these, around 40 players claim to offer both
libraries and technologies
§
Industry stakeholders offer either customized fragment
libraries or proprietary screening technologies, a select few claim to provide
both; however, the expertise related to fragment optimization is still limited
in this domain
§
Majority of stakeholders in the competitive market
landscape are small / mid-sized firms, offering a variety of services to cater
to the needs of a diverse clientele, featuring industry and non-industry
players
§
Stakeholders are actively expanding their capabilities in
order to enhance their respective fragment-based drug discovery service
portfolios and thereby, maintain a competitive edge in this upcoming industry
§
The rising interest in this field
is reflected in the number of partnerships inked in the recent past, involving
both international and indigenous stakeholders, and focused on drug discovery
for diverse range of indications
§
Considering the prevalent trend of drug discovery and
approval, we are led to believe that the fragment-based approach has the
potential to enable significant time and cost savings
§
The market is expected to witness
growth at a CAGR of ~10%; the anticipated opportunity is likely to be
distributed across various types of screening techniques, services and
geographies
For more information, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html
Table of Contents
1. PREFACE
1.1.
Scope of the Report
1.2.
Research Methodology
1.3.
Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Development
3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Validation
3.3.3. Hit Generation
3.3.4. Hit-to-Lead
3.3.5. Lead Optimization
1.4.
High-Throughput Screening (HTS) and its
Limitations
3.5. Fragment-based Drug Discovery (FBDD)
Press Release:
Variation 2 (Format 3)
3.5.1. FBDD Strategies
3.5.2. Screening Techniques Used in FBDD
3.6. Challenges Related to FBDD
3.7. Future Perspectives
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Fragment-based Drug Discovery: List of
Library and Service Providers
4.2.1. Analysis by Year of Establishment of
Company
4.2.2. Analysis by Company Size and Geographical
Location
4.2.3. Leading Library and Service Providers:
Analysis by Number of Products
4.2.4. Analysis by Geography
4.2.5. Analysis by Type of Service Offered
4.2.6. Analysis by Type of Technique Used
4.2.7. Analysis by Other Services Offered
4.2.8. Analysis by End User
4.3. Fragment-based Drug Discovery: List of
Libraries and Technologies
4.3.1. Analysis by Type of Product
5. COMPANY PROFILES: FRAGMENT-BASED DRUG
DISCOVERY LIBRARY AND SERVICE
PROVIDERS
5.1. Chapter Overview
5.2. 2bind
5.2.1. Recent Developments and Future Outlook
5.3. Charles River Laboratories
5.3.1. Recent Developments and Future Outlook
5.4. ChemAxon
5.4.1. Recent Developments and Future Outlook
5.5. ComInnex
5.5.1. Recent Developments and Future Outlook
5.6. Creative Biolabs
5.6.1. Recent Developments and Future Outlook
5.7. Creative Biostructure
5.8. CRELUX
5.8.1. Recent Developments and Future Outlook
5.9. Domainex
5.9.1. Recent Developments and Future Outlook
5.10. Evotec
5.10.1. Recent Developments and Future Outlook
5.11. Red Glead Discovery
5.12. SARomics Biostructures
5.13. Shanghai ChemPartner
5.13.1. Recent Developments and Future Outlook
Press Release:
Variation 2 (Format 3)
5.14. Sygnature Discovery
5.14.1. Recent Developments and Future Outlook
5.15. Vernalis Research
5.15.1. Recent Developments and Future Outlook
6. PARTNERSHIPS AND COLLABORATIONS
6.1. Chapter Overview
6.2. Partnership Models
6.3. Fragment-based Drug Discovery Services
Market: List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Year of Partnership and Type of
Partner
6.3.4. Most Active Players: Analysis by Number of
Partnerships
6.3.5. Regional Analysis
6.3.6. Intercontinental and Intracontinental
Agreements
7. KEY ACQUISITION TARGETS
7.1.
Chapter Overview
7.2.
Scope and Methodology
7.3.
Scoring Criteria and Key Assumptions
7.4. Potential Strategic Acquisition Targets
in North America
7.5. Potential Strategic Acquisition Targets
in Europe
7.6. Potential Strategic Acquisition Targets
in Asia-Pacific
7.7. Concluding Remarks
8. COMPANY
COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Key Parameters
8.4. Competitiveness Analysis: Fragment-based
Drug Discovery Library and Service Providers
8.4.1. Fragment-based Drug Discovery Library and
Service Providers based in North America
8.4.2. Fragment-based Drug Discovery Library and
Service Providers based in Europe
8.4.3. Fragment-based Drug Discovery Library and
Service Providers based in Asia-Pacific
9.1. Chapter Overview
9.2. Key Assumptions and Parameters
9.3. Methodology
9.4. Overall
Cost Saving Potential Associated with FBDD, 2020-2030
9.5. Concluding
Remarks
10. MARKET FORECAST AND OPPORTUNITY
ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Fragment-based Drug Discovery
Market, 2020-2030
10.4. Global Fragment-based Drug Discovery
Market: Distribution by Type of Technique, 2020 and
2030
10.4.1. Fragment-based
Drug Discovery Market for X-ray Crystallography, 2020-2030
10.4.2. Fragment-based
Drug Discovery Market for Nuclear Magnetic Resonance, 2020-2030
10.4.3. Fragment-based
Drug Discovery Market for Surface Plasmon Resonance, 2020-2030
10.4.4. Fragment-based
Drug Discovery Market for Other Screening Techniques, 2020-2030
10.5. Global
Fragment-based Drug Discovery Market: Distribution by Type of Service, 2020 and
2030
10.5.1. Fragment-based
Drug Discovery Market for Library Screening, 2020-2030
Press Release: Variation 2 (Format 3)
10.5.2. Fragment-based
Drug Discovery Market for Fragment Screening, 2020-2030
10.5.3. Fragment-based
Drug Discovery Market for Fragment Optimization, 2020-2030
10.6. Global
Fragment-based Drug Discovery Market: Distribution by End User, 2020 and 2030
10.6.1. Fragment-based
Drug Discovery Market for Industry Players, 2020-2030
10.6.2. Fragment-based
Drug Discovery Market for Non-industry Players, 2020-2030
10.7. Global
Fragment-based Drug Discovery Market: Distribution by Geography, 2020 and 2030
10.7.1. Fragment-based
Drug Discovery Market in the US, 2020-2030
10.7.2. Fragment-based
Drug Discovery Market in Canada, 2020-2030
10.7.3. Fragment-based
Drug Discovery Market in the UK, 2020-2030
10.7.4. Fragment-based
Drug Discovery Market in France, 2020-2030
10.7.5. Fragment-based
Drug Discovery Market in Germany, 2020-2030
10.7.6. Fragment-based
Drug Discovery Market in Spain, 2020-2030
10.7.7. Fragment-based
Drug Discovery Market in Italy, 2020-2030
10.7.8. Fragment-based
Drug Discovery Market in Rest of Europe, 2020-2030
10.7.9. Fragment-based
Drug Discovery Market in China, 2020-2030
10.7.10. Fragment-based Drug Discovery Market in Japan,
2020-2030
10.7.11. Fragment-based Drug Discovery Market in India,
2020-2030
10.7.12.
Fragment-based Drug Discovery Market in Rest of Asia-Pacific and Rest of the
World, 2020-
2030
11.
EXECUTIVE INSIGHTS
11.1.
Chapter Overview
11.2.
Edelris
11.2.1. Company Snapshot
11.2.2. Interview Transcript: Jean-Yves Ortholand,
Co-founder & Chief Executive Officer
11.3. SARomics Biostructures
11.3.1. Company Snapshot
11.3.2. Interview Transcript: Björn Walse, Chief
Executive Officer
12. CONCLUDING REMARKS
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND
ORGANIZATIONS
Gaurav Chaudhary
+1 (415) 800 3415
Comments
Post a Comment